HAXIDIA 10

INDICATIONS:
Haxidia 10 is indicated for the treatment of non-insulin-dependent diabetes mellitus (type 2), when hyperglycemia cannot be controlled by diet and exercise.

DOSAGE AND ADMINISTRATION:
How to use:
Like other hypoglycemic drugs, the dose must be adjusted for each patient.
Take once in the morning. Take about 30 minutes before meals to minimize postprandial blood glucose levels.

Dosage:
The dose of glipizide is determined based on the results of blood and urine glucose tests, and must be individualized for each patient to achieve optimal results. Patients must be closely monitored to determine the minimum effective dose of glipizide and to detect primary or secondary drug failure. If the appropriate dose is not taken correctly, hypoglycemia may occur. For patients who have had their blood glucose levels well controlled by diet but have temporarily lost control, glipizide can be used for a short time.

Initial dose: 5 mg x 1 time/day, taken before breakfast or lunch. Patients with mild diabetes, the elderly, and patients with liver disease should start with a dose of 2.5 mg x 1 time/day.

Dose increase: The dose is increased by 2.5 mg or 5 mg per day at least every few days (usually 3 - 7 days) depending on the patient's tolerance and treatment response.

Maintenance dose: Some patients can be effectively controlled with a once-daily dose. When using a dose of 15 mg/day, it should be divided into several doses during the day. The maximum dose is 20 mg/day.

Children: The safety and effectiveness of the drug in pediatric patients have not been established.

Elderly and high-risk patients: Elderly, debilitated patients, patients with renal or hepatic impairment, use caution when using the initial and maintenance doses to avoid hypoglycaemic reactions.

Patients currently taking other hypoglycaemic agents:

Switching from an oral antidiabetic sulfonylurea to glipizide: No transition period is required, the previous drug can be discontinued immediately. For chlorpropamide, because of its long elimination half-life, there is a risk of hypoglycaemia, so close monitoring is required during the first 2 weeks of the transition period when using glipizide.
Switching from insulin to glipizide: If you are using an insulin dose of 20 units/day or less, you can switch directly to the first recommended dose of regular glipizide and stop the insulin immediately. If the insulin dose is higher than 20 units/day, you should give the first recommended dose of regular glipizide and reduce the insulin dose by about 50%. Then, at least a few days apart, reduce the insulin dose and the glipizide dose by 2.5 - 5 mg/day each time. During the period of stopping insulin, urine should be checked for sugar and ketones 3 times a day. If the insulin dose is higher than 40 units/day, hospitalization is recommended.

Combining glipizide with other oral antidiabetic drugs: As with other sulfonylureas, some patients treated with glipizide alone do not achieve good results, and a second oral antidiabetic drug can be combined. In this case, the glipizide dose is kept as before, the second combination drug should be used at the lowest recommended dose, then gradually increased until the effect is achieved or restored.

Select another product in case the patient needs to use glipizide 2.5 mg.

CONTRAINDICATIONS:
Hypersensitivity to glipizide, other sulfonylureas or sulfonamides or to any of the excipients.
Insulin-dependent type 1 diabetes mellitus, especially juvenile diabetes, diabetic ketoacidosis, diabetic pre-coma.
Severe renal or hepatic impairment.
Patients receiving treatment with miconazole.
Surgery, pregnancy, lactation: Insulin replacement is required.